Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS

Non-invasive follow-up of urinary tract cancers

Ziel

Bladder cancer is the most common malignancy of the urinary tract with 573,000 new cases and 213,000 deaths in 2020 worldwide and affecting more men than women in a 4:1 ratio. Bladder cancer has the highest lifetime treatment costs per patient of all cancers, which is mainly attributed to the intensive follow-up procedures of patients after diagnostics and surgery. Follow-up is made recurring to extremely invasive and low-patient compliant tests.
ENSURE aims to validate the technological and business feasibility of the electronic nose technology developed in the ERC Starting Grant SCENT by establishing the proof-of-concept for the non-invasive follow-up of bladder cancer patients. To accomplish this, we will approach the project from both Technical and Business perspectives, with a perfect synergy between the research and business teams, and a close contact with clinical collaborators and stakeholders.

Wissenschaftliches Gebiet (EuroSciVoc)

Programm/Programme

Thema/Themen

Finanzierungsplan

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Alle im Rahmen dieses Finanzierungsinstruments finanzierten Projekte anzeigen

Aufforderung zur Vorschlagseinreichung

(öffnet in neuem Fenster) ERC-2022-POC1

Alle im Rahmen dieser Aufforderung zur Einreichung von Vorschlägen finanzierten Projekte anzeigen

Gastgebende Einrichtung

NOVA ID FCT - ASSOCIACAO PARA A INOVACAO E DESENVOLVIMENTO DA FCT
Netto-EU-Beitrag
€ 115 000,00
Adresse
CAMPUS DE CAPARICA FACULDADE DE CIENCIAS E TECNOLOGIA DA UNIVERSIDADE NOVA DE LISBOA
2829 516 Caparica
Portugal
Aktivitätstyp
Research Organisations
Links
Gesamtkosten
Keine Daten

Begünstigte (2)